Molnupiravir

不會吧?

最近天氣很冷，機器狼都很想喝熱呼呼的飲料呢汪 (｡・ω・｡)

Dosing: Adult

COVID-19, treatment, mild to moderate (outpatients with high risk of progression to severe illness) (alternative agent): Oral: 800 mg every 12 hours for 5 days; initiate as soon as possible after COVID-19 diagnosis, and within 5 days of symptom onset.

After initiating treatment with molnupiravir, if hospitalization is required, completion of 5-day course is at the health care provider's discretion (FDA 2021; Jayk Bernal 2021; NIH 2021).

Missed dose: If a dose is missed within 10 hours of usual administration time, administer the missed dose as soon as possible, and resume normal dosing schedule.

If a dose is missed by more than 10 hours, do not administer the missed dose, and resume dosing at the next scheduled administration time. Do not double the dose to make up for a missed dose (FDA 2021).

適用對象為具以下任一重症風險因子，未使用氧氣且於發病五天內之 ≧ 18歲病患，且無法使用其他建議藥物者；風險因子包括年齡 ≧ 65歲、糖尿病、慢性腎病、心血管疾病(含高血壓)、慢性肺疾、BMI ≧ 25、其他影響免疫功能之疾病或已知重症風險因子者。

建議劑量為molnupiravir 800mg每日兩次口服，療程共五天。